share_log

AbbVie | 8-K: AbbVie Reports First-Quarter 2024 Financial Results

AbbVie | 8-K: AbbVie Reports First-Quarter 2024 Financial Results

艾伯维公司 | 8-K：艾伯维公布2024年第一季度财务业绩
美股sec公告 ·  04/26 19:48
牛牛AI助手已提取核心信息
On April 26, 2024, AbbVie Inc. reported its financial results for the first quarter ending March 31, 2024. The company announced a slight increase in net revenues to $12.310 billion, up 0.7% on a reported basis and 1.6% on an operational basis. Despite facing competition from Humira biosimilars, which led to a 3.9% decrease in global net revenues from the immunology portfolio, AbbVie saw growth in other areas. The oncology portfolio increased by 9.0% on a reported basis, and the neuroscience portfolio by 15.9%. The aesthetics portfolio experienced a 4.0% decrease. AbbVie's GAAP diluted EPS was $0.77, a significant increase from the previous year, while the adjusted diluted EPS was $2.31, a decrease of 6.1%. The company also completed the acquisition of ImmunoGen, adding the cancer therapy Elahere to its portfolio. AbbVie raised its full-year adjusted diluted EPS guidance from $10.97 - $11.17 to $11.13 - $11.33. Additionally, Robert A. Michael was announced as the new CEO, succeeding Richard A. Gonzalez effective July 1, 2024. The company's shares are traded on the New York Stock Exchange under the ticker ABBV.
On April 26, 2024, AbbVie Inc. reported its financial results for the first quarter ending March 31, 2024. The company announced a slight increase in net revenues to $12.310 billion, up 0.7% on a reported basis and 1.6% on an operational basis. Despite facing competition from Humira biosimilars, which led to a 3.9% decrease in global net revenues from the immunology portfolio, AbbVie saw growth in other areas. The oncology portfolio increased by 9.0% on a reported basis, and the neuroscience portfolio by 15.9%. The aesthetics portfolio experienced a 4.0% decrease. AbbVie's GAAP diluted EPS was $0.77, a significant increase from the previous year, while the adjusted diluted EPS was $2.31, a decrease of 6.1%. The company also completed the acquisition of ImmunoGen, adding the cancer therapy Elahere to its portfolio. AbbVie raised its full-year adjusted diluted EPS guidance from $10.97 - $11.17 to $11.13 - $11.33. Additionally, Robert A. Michael was announced as the new CEO, succeeding Richard A. Gonzalez effective July 1, 2024. The company's shares are traded on the New York Stock Exchange under the ticker ABBV.
2024年4月26日，艾伯维公司公布了截至2024年3月31日的第一季度财务业绩。该公司宣布净收入小幅增长至123.10亿美元，按报告计算增长0.7％，运营收入增长1.6％。尽管面临来自Humira生物仿制药的竞争，导致免疫学产品组合的全球净收入下降了3.9％，但艾伯维在其他领域仍实现了增长。根据报告，肿瘤学投资组合增长了9.0％，神经科学投资组合增长了15.9％。美学投资组合下降了4.0％。艾伯维的GAAP摊薄后每股收益为0.77美元，比上年大幅增长，而调整后的摊薄每股收益为2.31美元，下降6.1％。该公司还完成了对ImmunoGen的收购，将癌症疗法Elahere添加到其投资组合中。艾伯维将其调整后的全年摊薄后每股收益预期从10.97美元至11.17美元上调至11.13美元至11.33美元。此外，罗伯特·迈克尔被宣布为新任首席执行官，接替理查德·冈萨雷斯，自2024年7月1日起生效。该公司的股票在纽约证券交易所上市，股票代码为ABBV。
2024年4月26日，艾伯维公司公布了截至2024年3月31日的第一季度财务业绩。该公司宣布净收入小幅增长至123.10亿美元，按报告计算增长0.7％，运营收入增长1.6％。尽管面临来自Humira生物仿制药的竞争，导致免疫学产品组合的全球净收入下降了3.9％，但艾伯维在其他领域仍实现了增长。根据报告，肿瘤学投资组合增长了9.0％，神经科学投资组合增长了15.9％。美学投资组合下降了4.0％。艾伯维的GAAP摊薄后每股收益为0.77美元，比上年大幅增长，而调整后的摊薄每股收益为2.31美元，下降6.1％。该公司还完成了对ImmunoGen的收购，将癌症疗法Elahere添加到其投资组合中。艾伯维将其调整后的全年摊薄后每股收益预期从10.97美元至11.17美元上调至11.13美元至11.33美元。此外，罗伯特·迈克尔被宣布为新任首席执行官，接替理查德·冈萨雷斯，自2024年7月1日起生效。该公司的股票在纽约证券交易所上市，股票代码为ABBV。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。